LIDDS: Update of News Release sent on November 9, 2019, with PDF-file: New Company Update and Market Valuation from Redeye
December 10, 2019 02:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ)Redeye has published a new LIDDS Company Update and Market Valuation, see attached file. For additional information, please contact: Monica Wallter, CEO LIDDS, +46...
LIDDS: New Company Update and Market Valuation from Redeye
December 09, 2019 08:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ)Redeye has published a new LIDDS Company Update and Market Valuation, see below link or PDF...
LIDDS Interview with the LPC-004 study investigator, Professor Laurence Klotz, about the LIDDS Liproca® Depot Phase IIb study results
December 02, 2019 05:15 ET
|
LIDDS AB
An interview with Professor Laurence Klotz, one of the LPC-004 study investigators was done in connection to the 11th European Multidisciplinary Congress on Urological Cancers, EMUC19 in which he...
LIDDS Delårsrapport juli – September 2019
November 28, 2019 02:30 ET
|
LIDDS AB
JULI – SEPTEMBER 2019Nettoomsättningen uppgick till 0,0 (7,8) MSEKKostnaderna uppgick till -2,8 (-2,5) MSEKResultatet före och efter skatt uppgick till -2,8 (5,4) MSEKResultat per aktie uppgick till...
LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met
November 16, 2019 04:10 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) Phase IIb clinical data from the LPC-004 prostate cancer study on LIDDS Liproca® Depot were presented today in an oral session at the 11th European Multidisciplinary...
LIDDS completes a direct share issue raising SEK 9.0 million
November 15, 2019 02:30 ET
|
LIDDS AB
The board of directors of LIDDS AB has decided to carry out a directed issue of 562,500 shares at a subscription price of SEK 16 per share. LIDDS will through the directed share issue receive proceeds...
LIDDS licensee Jiangxi Puheng Pharma prepares for phase III trial in China
November 07, 2019 03:45 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) Jiangxi Puheng Pharma has after reviewing the preliminary results in LPC-004 decided to move ahead and has initiated discussions with Chinese medical authority, CFDA....
LIDDS adds Lithuanian clinics to phase I study
November 06, 2019 02:45 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) has received approval from authorities in Lithuania to conduct its Phase I study, NZ-DTX-001. Previously the phase I study is approved in Sweden and Denmark. The...
LIDDS: Liproca® Depot open label extension study indicates PSA reduction for up to one year
October 23, 2019 02:30 ET
|
LIDDS AB
UPPSALA, SWEDEN. LIDDS AB (publ) – Data from a voluntary open label extension (OLE) study indicates longer PSA effect with Liproca® Depot in prostate cancer patients than anticipated. In half of the...
LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ)
September 24, 2019 13:00 ET
|
LIDDS AB
UPPSALA, SWEDEN. LIDDS AB (publ) – Due to a technical error by a market data provider, Wikow Invest was removed as largest shareholder in Top 10 tables at several trading and information sites over...